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Abstract 
Aims: Bowel symptoms, pelvic organ prolapse, and sexual dysfunction are common, but their frequency among 
women with lower urinary tract symptoms (LUTS) has not been well described. Our aims were to describe pelvic floor 
symptoms among women with and without urinary incontinence (UI) and among subtypes of UI. 
Methods: Women with LUTS seeking care at six U.S. tertiary care centers enrolled in prospective cohort study were 
studied. At baseline, participants completed the Pelvic Floor Distress Inventory (PFDI-20), Pelvic Organ 
Prolapse/Incontinence Sexual Questionnaire (PISQ-IR), and PROMIS GI Diarrhea, Constipation, and Fecal 
Incontinence Scales.  
Results: Mean age among the 510 women was 56.4 ± 14.4 years. Women who reported UI (n=420) had more diarrhea 
and constipation symptoms (mean scores 49.5 vs 46.2 [p=0.01] and 51.9 vs 48.4 [p<0.01], respectively) at baseline. 
Among sexually active women, mean PISQ-IR subscale scores were lower among those with UI (condition specific: 
89.8 vs 96.7, p<0.01; condition impact: 79.8 vs 92.5, p<0.01). Women with mixed urinary incontinence (MUI) (n=240) 
reported more prolapse symptoms, fecal incontinence, and worse sexual function compared to those with stress urinary 
incontinence (SUI) and urgency urinary incontinence (UUI).  
Conclusions: Women presenting with LUTS with UI reported significantly worse constipation, diarrhea, fecal 
incontinence, and sexual function compared to women without UI. In women with UI, sexual function and pelvic organ 
prolapse (POP) symptoms were worse in those with MUI compared to SUI and UUI. 
KEYWORDS: constipation, fecal incontinence, pelvic organ prolapse, urinary incontinence  
 
 
Introduction 
Symptoms of pelvic-floor disorders including constipation, diarrhea, and fecal incontinence as well as pelvic organ 
prolapse and sexual dysfunction are common in women. These disorders occur concurrently with urinary incontinence 
(UI); however, the relationship has not been well described. Pelvic floor dysfunction is common to all of these 
disorders which is why aging and childbirth which both affect the pelvic floor are factors that concurrently affect 
multiple pelvic floor organs in adult women. It has been reported that women with difficult defecation have more 
urinary urgency and frequency, but not UI; however, this is controversial1. Women with obstetrical anal injury are at 
increased risk not only for fecal incontinence but also stress urinary incontinence (SUI)2.  
Pelvic organ prolapse has consistently been associated with urinary urgency and urgency incontinence (UUI), with the 
relationship possibly being causal since correction of the prolapse or placement of a pessary can relieve these bladder 
Au
tho
r M
an
us
cri
pt
symptoms3. Also, the relationship between prolapse and SUI is complex, as SUI often occurs concurrently with 
prolapse, but prolapse may also be protective as correction of prolapse often unmasks occult SUI 4.  
The association between UI and sexual activity remains uncertain. Prior studies have provided conflicting results, with 
patient age and partner status as possible significant factors5,6. Mixed urinary incontinence (MUI) has the greatest 
negative impact on sexual function compared to SUI and UUI7. 
The aims of this study were: 1) to determine the relationships between bowel symptoms including constipation, 
diarrhea, and fecal incontinence, prolapse symptoms, and sexual function among women seeking care for lower urinary 
tract symptoms (LUTS); and 2) to evaluate whether the presence of UI, or UI subtype, is associated with the severity of 
these symptoms.  
Material and Methods 
Study Design and Population 
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We report on women enrolled in a one-year, multi-center, prospective observational cohort study from the 
NIH/NIDDK-sponsored Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). Details of this 
cohort study have been previously reported 8. Briefly, participants were at least 18 years of age, presented to a LURN 
physician for the first time seeking care for their LUTS, and reported at least one LUTS Tool9 symptom using a one-
month recall screening period. We modified the LUTS Tool, with permission from Pfizer, to capture a recall period of 
one month for the LURN study. Data collection at the baseline visit for women included a standardized clinical 
examination including pelvic examination with Pelvic Organ Prolapse Quantitation (POP-Q), assessment of pelvic 
floor muscle strength with the Oxford scale, urinalysis, and measurement of post-void residual. Medical history 
including functional comorbidity index (FCI), patient-reported symptoms of LUTS, pelvic floor symptoms, and 
psychological symptoms was also collected. Quality of life was obtained by validated questionnaires 10–13. 
Measures 
Seven questions regarding UI on the LUTS Tool 9 were used to determine presence of UI. Women who reported 
“rarely” or “never” to these questions were classified as “without UI”, and responses of “sometimes” or greater on at 
least one symptom of UI during exercise, laughing/sneezing/coughing, feelings of urinary urgency, sleep, sex, or for no 
reason were classified as “with UI.” Participants were further classified as having SUI if they answered “sometimes” or 
more on at least one of two questions related to experiencing leakage while exercising or during a laugh, cough, or 
sneeze. Those who responded “sometimes” or more to leakage due to a sudden feeling of needing to rush to urinate 
were classified as having UUI. Those with both SUI and UUI were classified as MUI. Those participants with UI who 
did not meet criteria for SUI, UUI, or MUI were classified as Other UI. 
A continuous UI severity measure was also calculated using the 7 LUTS Tool UI questions. For each study participant, 
the weighted Euclidean length (square root of sum of squared responses) was calculated to form a UI severity score 
(range 1.84-9.44). Questions were weighted by the ratio of the average correlation between a given question and all 
other questions to the total average correlation so that less weight was given to questions that had high correlation with 
other questions (e.g., multiple questions assessing SUI)14.  
Participants also completed the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA Revised (PISQ-IR)10, 
Genitourinary Pain Index (GUPI)11, Pelvic Floor Distress Inventory-20 (PFDI-20) 12, and Patient-Reported Outcomes 
Measurement Information System (PROMIS) GI Constipation, Diarrhea, and Fecal Incontinence scales13. The PFDI-20 
is a condition-specific quality of life measure that assesses bother related to pelvic floor symptoms and includes three 
scales, the Urinary Distress Inventory (UDI-6), Pelvic Organ Prolapse Distress Inventory (POPDI-6), and Colo-Rectal-
Anal Distress Inventory (CRADI-8). Each scale is scored 0-100 with a higher score indicating greater bother. The 
PISQ-IR measures sexual function in women with pelvic floor disorders separately for sexually and not sexually active 
women. A higher score on the subscale indicates better sexual function. There is no summary score for the PISQ-IR.  
PROMIS measures used short forms to derive T-scores normalized to the U.S. population as a reference (by definition, 
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mean=50, standard deviation [SD] = 10). One exception was fecal incontinence, which uses a raw score as the metric. 
Higher scores on PROMIS measures indicate more symptoms. 
Statistical Methods 
Characteristics of the participants are shown as means, standard deviations, frequencies, and percentages. Tests for 
differences by group were performed using chi-square tests and Wilcoxon two-sample tests or Kruskal-Wallis tests. 
Descriptive statistics were calculated for sexual function, pelvic floor, and bowel symptom measures; differences 
between groups were tested using one-way ANOVA and Cohen’s d was used to calculate effect sizes. Urinary 
subscales (GUPI urinary subscale and UDI-6 subscale of PFDI-20) and summary scores including urinary subscales 
were excluded due to similarity to LUTS Tool questions.  
Multivariable linear regression was used to test for associations between incontinence status (UI vs. non-UI) and sexual 
function, pelvic floor, and bowel measures. Candidate covariates included age, race, ethnicity, body mass index (BMI), 
education, employment status, smoking status, diabetes, sleep apnea, functional comorbidity index (FCI), menopausal 
status (with and without hormone use), history of psychiatric diagnosis, previous brain or spinal surgery, more than two 
urinary tract infections in the past year by self-report, hysterectomy, any vaginal births, and alcohol consumption. Best 
subset selection guided covariate selection for all models. Similar models were created to test for associations between 
the outcomes and UI subtype (SUI, UUI, and MUI, with MUI as the reference category due to its prevalence and 
increased severity) and UI severity. Data on POP-Q and pelvic floor strength (Oxford scale) were each missing in 20% 
of participants and were excluded as potential covariates; however, they were tested in separate sub-analyses. All p-
values were adjusted for multiple comparisons using the false discovery rate (FDR) correction. All analyses were 
conducted using SAS 9.4 (SAS Institute, Cary, NC).  
Results  
Among 545 women recruited from the six sites, 510 with complete responses to the 7 LUTS Tool questions required 
for UI subtyping were included in the present analyses. Mean age was 56.4 ±14.4 years; most were Caucasian (82%) 
(Table 1). Mean BMI was 30.6 ±7.8 kg/m 2, and 15% reported a history of diabetes. A median of two vaginal births was 
reported. Sixty-four percent were post-menopausal and 17% used estrogen treatment (topical or systemic).  Sixty-three 
percent had a stage 0 or 1 pelvic organ prolapse on physical exam, 30% had stage 2, and 6% had stage 3 or 4.  At 
baseline, few study participants reported taking an anti-muscarinic drug (2%) or medication to relieve constipation 
(6%). Thirty percent had prior hysterectomy, and 14% had undergone surgery for UI and/or prolapse. One-half of the 
women were sexually active (51%). The mean functional comorbidity index was 2.4 ±2.2 for the group, and mean post-
void residual was 44.8 ±58.7 ml.  
Overall, 90 (18%) women reported no more than rarely having incontinence on any of the seven incontinence questions 
(16a-g) on the LUTS tool and were considered “without UI.” Compared to the 420 women with UI, those without UI 
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had lower mean BMI (28.2 vs. 31.1, p=0.002), were less likely to have recurrent urinary tract infections in the prior 
year (37% vs. 50%, p=0.029), and had fewer self-reported comorbidities (FCI 1.9 vs. 2.5, p=0.012). Of the 420 women 
with UI, most had MUI (57%), 20% had UUI, and 17% SUI. Six percent (n=25) had Other UI. Women reporting MUI 
were older, with higher BMI, higher prevalence of smoking and sleep apnea, and more comorbidities compared to 
women with UUI or SUI only. Women with MUI had significantly higher UI severity compared to women with SUI or 
UUI (Figure 1). Average UI severity in the MUI group was 5.39±1.54 compared to 3.98±1.48 (SUI) and 3.31±1.13 
(UUI) (all p<0.001).  
 Associations between sexual functioning and UI 
In terms of sexual dysfunction, only a few of the PISQ subscales were significantly different between groups. Among 
sexually active women only, the PISQ-SA Condition Impact and Condition Specific subscales were lower (worse 
function) in women with UI (mean scores 79.8 [UI] vs. 92.5 [non-UI], p<0.001 and 89.8 [UI] vs. 96.7 [non-UI], 
p=0<0.001) compared to women without UI, and these differences remained significant after adjusting for BMI, 
smoking status, and parity.  
Among women with UI who reported they were sexually active, those with MUI reported lower mean scores on PISQ 
SA-Condition Impact subscale (worse function) (average 73.3) compared to women with SUI (average 86.3) and 
women with UUI (average 87.4). These differences remained significant after covariate adjustment (Supplemental 
Table 1). Urinary incontinence occurring during sexual intercourse was more common in the SUI and MUI groups, 
with 17% and 18%, respectively, compared to only 4% in the UUI group (p=0.004). Women who reported more severe 
UI, regardless of subtype, had significantly worse sexual function on the PISQ SA-Condition Specific (on average 3.05 
point reduction in PISQ score per unit increase in UI severity, p<0.001) and Condition Impact measures (on average 
2.64 point reduction in PISQ score per unit increase in UI severity, p=0.01).  
Associations between prolapse symptoms and UI 
Bother associated with prolapse was marginally higher in women with UI (average POPDI-6 scores 17.1 vs. 13.8, 
p=0.10, Table 2), although measures of anterior and posterior vaginal wall descent did not differ between the two 
groups. Among those with UI, women with MUI reported more bother associated with prolapse (average POPDI-6 
scores 20.6 compared to 10.7 [UUI] and 12.4 [SUI], p<0.001, Table 3), and these differences remained statistically 
significant after adjustment. In all women, as UI severity increased, women reported worse pelvic floor distress on the 
POPDI-6. 
Associations between bowel function and UI 
Compared to those without UI, women with UI had higher PROMIS Constipation (51.9 vs. 48.4, p=0.003), and 
Diarrhea scores (49.5 vs. 46.2, p=0.008), indicating worse bowel function (Table 2). On multivariable linear regression 
of these bowel function measures adjusted for other statistically significant covariates (Supplementary Table 2), these 
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results were only minimally changed. CRADI-8 scores were also higher for women with UI (21.0 vs. 14.8, p=0.02), but 
this difference did not remain statistically significant after adjustment for comorbidities and parity. 
Among those with UI, the MUI group experienced more bowel symptoms and had higher (worse) PROMIS scores for 
diarrhea and fecal incontinence (Table 1). There were no significant differences in PROMIS Constipation scores among 
the various UI subtypes with MUI as the reference category. CRADI-8 scores were also higher (more bother) among 
the MUI group compared with SUI and UUI groups. After adjustment, the differences remained between the MUI and 
SUI groups, but not between MUI and UUI. As UI severity increased, bowel function worsened on all three PROMIS 
bowel measures; CRADI-8 scores measuring bother related to bowel function also increased. Full models are available 
in Supplemental Table 3. 
Discussion 
We report the relationships between UI and other pelvic floor symptoms and quality of life measures, including bowel, 
prolapse, and sexual function, in over 500 women seeking care for LUTS. Overall, our results show that in women with 
LUTS: (1) the presence of UI is associated with constipation and poor sexual function; (2) MUI is associated with 
worse fecal incontinence, diarrhea, pelvic organ prolapse symptoms, and sexual function compared to SUI; and (3) 
more severe UI symptoms, regardless of UI subtype, are associated with worse bowel function (fecal incontinence, 
diarrhea, constipation), pelvic organ prolapse symptoms, and sexual function.  
Although it is well known that UI adversely affects sexual function in women, less is known about the effects of UI 
subtypes. Conflicting results were reported in three studies, which identified UI subtypes by urodynamic testing and 
assessed sexual function (in sexually active women) through PISQ-12 scores6,7,15. Two of these studies found SUI 
patients had worse sexual function than UUI patients6,7, and one found MUI patients had the poorest sexual function7. 
The third study found no difference in sexual function between all three UI subtypes 16. All of these studies were 
limited by small sample sizes and their results were not adjusted for potentially important covariates, such as age, BMI, 
and comorbidities. In contrast to these prior results, we found poorer sexual function in women with MUI among 
sexually active women, but no large differences in function between stress and urgency UI subtypes using a much 
larger sample of women and multivariable analysis. 
The association between pelvic organ prolapse and UI has pathophysiological basis. SUI commonly occurs with pelvic 
organ prolapse, due to similar pelvic floor injury causing urethral hypermobility and/or some degree of intrinsic 
sphincter deficiency. UUI may also have a strong relationship to pelvic organ prolapse17 since POP may cause bladder 
outlet obstruction and overactive bladder symptoms. A large cystocele may also put traction on the urethra, resulting in 
an open urethra. Surgical repair of pelvic organ prolapse has been shown to improve UUI in the majority of patients3 . 
Levator ani pelvic floor muscle injury, sphincteric injury, and/or pudendal nerve injury may be also present in a subset 
of patients who have concomitant UI, pelvic organ prolapse, and fecal incontinence218,19. Thus, our finding that 
increasing UI severity was associated with more distress from prolapse symptoms was not surprising. 
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Regarding bowel function, past studies have similarly demonstrated that constipation, difficult defecation, and fecal 
incontinence occur commonly in women with LUTS20-22. Studies performed in specialty clinic populations have 
demonstrated associations between functional constipation and overactive bladder22, and a high prevalence (19%) of 
fecal incontinence in women seeking care for urinary incontinence20 . However, there have only been a few studies that 
have examined the effects of UI subtypes on bowel dysfunction. Meschia et al. suggested that anal incontinence is more 
prevalent among patients with MUI and UUI than SUI (28.8%, 28.7%, and 21.8%, respectively)23. We have also 
demonstrated increased bowel dysfunction (fecal incontinence and diarrhea) in women with mixed UI, compared to 
SUI. Our results strengthen these prior findings with the use of validated PROMIS questionnaires (rather than a non-
validated screening questionnaire) to assess the bowel symptoms and multivariable analysis to adjust for potential 
confounding variables. 
There are several theoretical explanations for the association between bowel and bladder dysfunction. Both the bladder 
and bowel originate embryologically from the same cloaca and, given the proximity of the bowel and bladder in the 
pelvis, a distended rectal vault could have a mass effect on the bladder. Both the distal bowel and bladder share afferent 
nerves, as well, explaining why sacral neuromodulation is used to treat both bowel and bladder incontinence. Studies 
on the treatments of one organ resulting in a positive impact on other pelvic organs are lacking in adults. However, it 
has been clearly demonstrated that aggressive treatment of constipation in children with dysfunctional elimination 
without any bladder intervention frequently results in resolution of UI12. These theories may explain why women with 
MUI have worse bowel function since they likely have combined anatomic (loss of support) and neurologic deficits.  
Our study has several important strengths. First, we used a condition-specific questionnaire (PISQ-12) to assess sexual 
function in women with pelvic floor disorders. The questionnaire has undergone validation in this patient population 
and assesses both sexually active and non-active women10. Second, bowel symptoms were assessed using validated 
PROMIS questionnaires13. Finally, unlike many previous studies that were typically from a single center with small 
sample size, we have recruited a large number of women prospectively across several sites; this may enhance the 
generalizability of our findings to other care-seeking women in different clinical care settings.  
Our study has several limitations. As it entails cross-sectional comparisons, the causal relationship of one symptom to 
another cannot be inferred. The classification into SUI, UUI, and MUI was based on self-reported symptoms on the 
LUTS Tool questionnaire, and not urodynamic findings. Also, patients were recruited at tertiary academic centers with 
expertise in managing LUTS. Thus, our results may be less generalizable to women who seek treatment with 
community urologists, gynecologists, or primary care physicians. On the other hand, relatively few women reported 
taking anticholinergic medications (2%) or had had prior pelvic surgery for UI at study entry (14%), suggesting our 
participants did not include many complex or refractory cases. Finally, the UI severity measure reported here has not 
been validated and therefore results regarding UI severity may not be reproducible in other populations. 
Conclusion 
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Among women seeking care for LUTS, those with UI symptoms, mixed UI, and/or more severe UI were more likely to 
report poorer bowel dysfunction, prolapse symptoms, and worse sexual function. Our findings suggest that health care 
providers should question their patients seeking care for LUTS to identify and manage co-occurring pelvic floor 
dysfunctions. 
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Legends 
 
 
Figure 1: UI Severity by subtype. UI severity was calculated as the weighted Euclidean distance (square root of sum of squared 
responses) of 7 LUTS Tool incontinence questions. Weights were calculated using the ratio of average correlation of a given 
question to the average total correlation of all 7 questions in order to account for potential redundancy in questions. 
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Table 1: Demographics and medical history of LURN female cohort 
 
 
Total 
(n=510) 
Non-UI  
(n=90) 
UI 
(n=420) p-value* 
SUI  
(n=70) 
UUI 
(n=85) 
Mixed UI 
(n=240) p-value** 
Age 56.4 (14.4) 55.8 (17.1) 56.6 (13.8) 0.953 56.8 (15.8) 53.0 (13.4) 57.6 (13.1) 0.022 
Race    0.448    0.178 
  American Indian/Alaskan Native 5 (1%) 2 (2%) 3 (1%)  1 (1%) 0 (0%) 1 (0%)  
  Asian 14 (3%) 2 (2%) 12 (3%)  3 (4%) 4 (6%) 5 (2%)  
  African-American 59 (12%) 8 (9%) 51 (12%)  14 (16%) 6 (9%) 30 (13%)  
  Native Hawaiian/Pacific Islander 1 (0%) 0 (0%) 1 (0%)  1 (1%) 0 (0%) 0 (0%)  
  White 418 (82%) 74 (82%) 344 (82%)  62 (73%) 59 (84%) 200 (84%)  
  Multi-racial/Other 12 (2%) 4 (4%) 8 (2%) . 4 (5%) 1 (1%) 3 (1%)  
Education    0.159    0.204 
  < HS Diploma/GED 11 (2%) 1 (1%) 10 (2%)  1 (1%) 2 (3%) 7 (3%)  
  HS Diploma/GED 45 (9%) 4 (5%) 41 (10%)  6 (7%) 5 (7%) 29 (12%)  
  Some college/tech school - no 
degree 
117 (23%) 17 (20%) 100 (24%)  19 (22%) 10 (14%) 64 (27%)  
  Associate’s degree 57 (11%) 7 (8%) 50 (12%)  9 (11%) 11 (16%) 26 (11%)  
  Bachelor’s degree 153 (30%) 29 (34%) 124 (30%)  27 (32%) 21 (30%) 68 (29%)  
  Graduate degree 119 (24%) 28 (33%) 91 (22%)  23 (27%) 21 (30%) 42 (18%)  
Employment    0.145    0.054 
  Employed part-time 72 (14%) 12 (14%) 60 (14%)  14 (16%) 10 (14%) 35 (15%)  
  Employed full-time 197 (39%) 30 (34%) 167 (40%)  32 (38%) 38 (54%) 81 (34%)  
  Unemployed (looking for work) 14 (3%) 0 (0%) 14 (3%)  1 (1%) 3 (4%) 10 (4%)  
  Not employed (not looking for work) 221 (44%) 46 (52%) 175 (42%)  38 (45%) 19 (27%) 110 (47%)  
BMI 30.6 (7.8) 28.2 (5.9) 31.1 (8.1) 0.002 30.6 (7.9) 27.9 (6.4) 32.4 (8.3) <.001 
  < 25 137 (27%) 28 (32%) 109 (26%) 0.015 25 (29%) 30 (43%) 47 (20%) 0.006 
  25-30 131 (26%) 31 (36%) 100 (24%)  19 (22%) 17 (24%) 55 (23%)  
  30-35 108 (22%) 16 (18%) 92 (22%)  18 (21%) 13 (19%) 60 (26%) . 
  >35 126 (25%) 12 (14%) 114 (27%)  23 (27%) 10 (14%) 73 (31%)  
Current or Former Smoker 174 (35%) 22 (26%) 152 (37%) 0.050 22 (26%) 23 (33%) 96 (41%) 0.040 
Diabetes 74 (15%) 13 (15%) 61 (15%) 0.972 12 (14%) 6 (9%) 39 (16%) 0.257 
>2 UTIs in the past year 236 (48%) 32 (37%) 204 (50%) 0.029 34 (41%) 32 (46%) 128 (55%) 0.057 
Sleep Apnea 90 (18%) 10 (11%) 80 (19%) 0.087 12 (14%) 4 (6%) 59 (25%) <.001 
History of psychiatric diagnosis 218 (43%) 32 (36%) 186 (45%) 0.156 33 (39%) 26 (37%) 116 (49%) 0.104 
Previous brain or spinal surgery 37 (7%) 5 (6%) 32 (8%) 0.511 6 (7%) 1 (1%) 23 (10%) 0.071 
Number of Vaginal Births 1.7 (1.4) 1.5 (1.5) 1.8 (1.4) 0.148 1.7 (1.4) 1.7 (1.2) 1.8 (1.5) 0.606 
Post-menopausal 323 (64%) 52 (59%) 271 (66%) 0.245 59 (69%) 39 (56%) 155 (66%) 0.170 
  Hormone Use 55 (17%) 11 (21%) 44 (16%) 0.430 8 (14%) 12 (32%) 23 (15%) 0.034 
Anticholinergic medication use 11 (2%) 3 (3%) 8 (2%) 0.397 1 (1%) 1 (1%) 5 (2%) 0.838 
Anti-Constipation medication use 32 (6%) 8 (9%) 24 (6%) 0.260 5 (6%) 4 (6%) 13 (5%) 0.985 
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Total 
(n=510) 
Non-UI  
(n=90) 
UI 
(n=420) p-value* 
SUI  
(n=70) 
UUI 
(n=85) 
Mixed UI 
(n=240) p-value** 
Previous Surgeries (multiple 
possible)         
  Urgency incontinence 6 (1%) 0 (0%) 6 (1%) 0.254 1 (1%) 2 (3%) 3 (1%) 0.600 
  SUI/Prolapse 66 (13%) 10 (11%) 56 (13%) 0.569 11 (13%) 3 (4%) 38 (16%) 0.042 
  Hysterectomy 154 (30%) 23 (26%) 131 (31%) 0.328 27 (32%) 21 (30%) 76 (32%) 0.948 
  Urethral Dilation 3 (1%) 0 (0%) 3 (1%) 0.421 0 (0%) 0 (0%) 2 (1%) 0.523 
  Other 1 (0%) 0 (0%) 1 (0%) 0.643 0 (0%) 0 (0%) 1 (0%) 0.723 
Functional Comorbidity Index 2.4 (2.2) 1.9 (1.8) 2.5 (2.2) 0.012 2.2 (2.0) 1.9 (1.8) 2.8 (2.3) 0.002 
Prolapse    <.001    0.397 
  Stage 0 134 (31%) 34 (44%) 100 (28%)  25 (34%) 16 (27%) 50 (25%)  
  Stage 1 140 (32%) 17 (22%) 123 (35%)  27 (37%) 22 (37%) 69 (34%)  
  Stage 2 131 (30%) 15 (19%) 116 (33%)  20 (27%) 17 (28%) 74 (37%)  
  Stage 3 26 (6%) 11 (14%) 15 (4%)  1 (1%) 5 (8%) 8 (4%)  
  Stage 4 1 (0%) 0 (0%) 1 (0%) . 0 (0%) 0 (0%) 1 (0%)  
Anterior vaginal wall (Aa, cm) -1.7 (1.3) -1.7 (1.5) -1.7 (1.3) 0.520 -1.8 (1.3) -1.7 (1.2) -1.6 (1.3) 0.448 
Posterior vaginal wall (Ba, cm) -1.6 (1.9) -1.4 (2.3) -1.7 (1.8) 0.764 -1.8 (1.3) -1.3 (1.5) -1.7 (2.0) 0.214 
Pelvic Floor Muscle Strength (Oxford 
Scale)    0.501    0.082 
  Grade 0 39 (11%) 6 (9%) 33 (11%)  8 (13%) 4 (8%) 18 (11%)  
  Grade 1 81 (22%) 15 (22%) 66 (22%)  15 (25%) 12 (23%) 36 (21%)  
  Grade 2 84 (23%) 13 (19%) 71 (24%)  13 (21%) 8 (15%) 47 (28%)  
  Grade 2 80 (22%) 16 (23%) 64 (21%)  10 (16%) 12 (23%) 38 (22%)  
  Grade 4 61 (17%) 11 (16%) 50 (17%)  8 (13%) 13 (25%) 27 (16%)  
  Grade 5 24 (7%) 8 (12%) 16 (5%)  7 (11%) 4 (8%) 3 (2%)  
PVR (ml) 44.8 (58.7) 53.3 (68.4) 42.9 (56.2) 0.319 46.2 (63.8) 31.0 (56.1) 43.3 (52.7) 0.064 
Alcoholic Beverages Consumed Per 
Week    0.624    0.580 
  0-3 334 (68%) 62 (74%) 272 (66%)  58 (69%) 47 (67%) 150 (65%)  
  4-7 60 (12%) 8 (10%) 52 (13%)  12 (14%) 11 (16%) 24 (10%)  
  8-14 14 (3%) 2 (2%) 12 (3%)  3 (4%) 2 (3%) 7 (3%)  
  >14 3 (1%) 1 (1%) 2 (0%)  1 (1%) 0 (0%) 1 (0%)  
  Never consumed alcohol 83 (17%) 11 (13%) 72 (18%)  10 (12%) 10 (14%) 49 (21%)  
*P-value for wet vs. dry from chi-square test or Wilcoxon 2-sample test 
**P-value for SUI vs. UUI vs. Mixed UI from chi-square test or Kruskal-Wallis test 
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Table 2: Pelvic Floor Measures among Women with and without Urinary Incontinence 
 
Indices 
N Non-
UI 
Mean (SD) 
Non-UI 
N 
UI 
Mean (SD) 
UI 
p-
value* 
Adjusted 
p-value** 
PISQ NSA-Condition Specific 29 21.9 (21.3) 187 29.1 (30.0) 0.168  
PISQ NSA-Partner Related 31 60.7 (26.7) 192 59.8 (29.7) 0.912  
PISQ NSA-Global Quality 29 38.1 (32.8) 188 48.4 (33.1) 0.168  
PISQ NSA-Condition Impact 30 12.2 (22.3) 188 24.0 (31.7) 0.031 0.11 
PISQ SA-Arousal Orgasm 50 66.4 (19.0) 198 61.8 (19.7) 0.189  
PISQ SA-Partner Related 48 75.8 (24.6) 184 78.4 (24.5) 0.596  
PISQ SA-Condition Specific 49 96.7 (8.9) 195 89.8 (15.8) <.001 0.05 
PISQ SA-Global Quality 49 62.9 (26.9) 197 62.6 (30.4) 0.961  
PISQ SA-Condition Impact 49 92.5 (14.8) 198 79.8 (28.0) <.001 0.01 
PISQ SA-Desire 50 55.5 (21.9) 197 54.1 (21.9) 0.767  
GUPI Pain Subscale 65 4.1 (4.2) 300 4.7 (5.1) 0.461  
PFDI POPDI6 87 13.8 (14.2) 406 17.1 (20.0) 0.104  
PFDI CRADI8 87 14.8 (18.2) 404 21.0 (20.4) 0.022 0.15 
PROMIS GI Constipation T-score 86 48.4 (8.8) 404 51.9 (8.9) 0.003 0.02 
PROMIS GI Diarrhea T-score 88 46.2 (8.6) 410 49.5 (9.6) 0.008 0.02 
PROMIS GI Bowel Incontinence 
Raw Score 
87 4.8 (2.2) 389 5.4 (2.5) 0.058  
*P-value from t-test. 
**P-value from multivariable linear regression models. Models were built using best subset 
selection with potential adjustment variables listed in Table 1. Full model results can be found 
in Supplementary Table 1.   
PISQ=Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire; NSA = Not Sexually 
Active; SA = Sexually Active; GUPI = Genitourinary Pain Index; PFDI = Pelvic Floor Distress 
Inventory; POPDI = Pelvic Organ Prolapse Distress Inventory; CRADI = Colo-rectal-anal 
Distress Inventory; PROMIS = Patient-Reported Outcomes Measurement Information System; 
GI=Gastrointestinal 
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Table 3: Pelvic Floor Measures among Women by Urinary Incontinence Subtype 
 
 UUI SUI Mixed UI       
Indices N  
Mean 
(SD)  N  
Mean 
(SD)  N  
Mean 
(SD)  
Overall 
ANOVA 
p-value* 
SUI vs. 
Mixed  
p-value* 
UUI vs. 
Mixed  
p-value* 
Adjusted 
Overall 
p-value** 
Adjusted 
SUI vs. 
Mixed p-
value** 
Adjusted 
UUI vs. 
Mixed p-
value** 
PISQ NSA-
Condition 
Specific 
40 22.0 
(30.3) 
20 28.5 
(23.8) 
115 31.4 
(30.2) 
0.270 0.715 0.129    
PISQ NSA-
Partner Related 
42 69.4 
(29.0) 
20 43.3 
(21.3) 
118 58.8 
(29.5) 
0.010 0.049 0.074 0.004 0.04 0.03 
PISQ NSA-
Global Quality 
40 40.4 
(32.4) 
20 59.1 
(37.5) 
116 49.5 
(32.1) 
0.143 0.271 0.172    
PISQ NSA-
Condition 
Impact 
41 18.7 
(30.2) 
20 25.6 
(31.9) 
115 26.5 
(32.3) 
0.434 0.901 0.221    
PISQ SA-
Arousal Orgasm 
41 65.0 
(18.8) 
46 66.9 
(16.2) 
98 57.7 
(21.3) 
0.034 0.021 0.082 0.05 0.05 0.06 
PISQ SA-
Partner Related 
37 79.7 
(27.8) 
44 84.7 
(18.3) 
92 74.1 
(26.2) 
0.099 0.042 0.288    
PISQ SA-
Condition 
Specific 
41 93.2 
(14.4) 
45 91.3 
(12.4) 
96 87.1 
(18.1) 
0.136 0.198 0.078    
PISQ SA-Global 
Quality 
41 65.8 
(31.8) 
45 68.2 
(24.8) 
98 57.9 
(32.4) 
0.169 0.099 0.213    
PISQ SA-
Condition 
Impact 
42 87.4 
(24.4) 
45 86.3 
(22.6) 
98 73.3 
(29.9) 
0.010 0.019 0.013 0.01 0.05 0.01 
PISQ SA-Desire 41 56.1 
(23.9) 
45 52.9 
(20.0) 
98 53.8 
(22.8) 
0.811 0.836 0.616    
GUPI Pain 
Subscale 
57 4.0 
(4.6) 
55 4.2 
(4.7) 
170 5.0 
(5.4) 
0.388 0.346 0.258    
PFDI POPDI6 84 10.7 
(14.7) 
68 12.4 
(15.0) 
229 20.6 
(22.4) 
<.001 0.008 <.001 0.004 0.01 0.004 
PFDI CRADI8 84 18.3 
(19.0) 
68 12.8 
(13.7) 
227 24.3 
(21.4) 
<.001 <.001 0.036 0.02 0.01 0.20 
PROMIS GI 
Constipation T-
score 
85 50.9 
(8.3) 
66 50.3 
(8.6) 
229 52.6 
(9.0) 
0.139 0.099 0.169    
PROMIS GI 
Diarrhea T-
score 
85 47.9 
(9.1) 
68 46.0 
(8.7) 
232 51.3 
(9.8) 
<.001 <.001 0.013 0.01 0.01 0.07 
PROMIS GI 
Bowel 
Incontinence 
Raw Score 
82 5.2 
(2.3) 
63 4.5 
(1.2) 
220 5.8 
(2.9) 
0.004 0.002 0.099 0.01 0.004 0.10 
*P-values from one-way ANOVA with pairwise p-values for SUI vs. Mixed and UUI vs. Mixed. 
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 UUI SUI Mixed UI       
Indices N  
Mean 
(SD)  N  
Mean 
(SD)  N  
Mean 
(SD)  
Overall 
ANOVA 
p-value* 
SUI vs. 
Mixed  
p-value* 
UUI vs. 
Mixed  
p-value* 
Adjusted 
Overall 
p-value** 
Adjusted 
SUI vs. 
Mixed p-
value** 
Adjusted 
UUI vs. 
Mixed p-
value** 
**P-values from multivariable linear regression models (overall and pairwise for SUI vs. Mixed and UUI vs. Mixed). Models were 
build using best subset selection with potential adjustment variables listed in Table 1. Full model results can be found in 
Supplementary Table 2.   
PISQ=Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire; NSA = Not Sexually Active; SA = Sexually Active; 
GUPI = Genitourinary Pain Index; PFDI = Pelvic Floor Distress Inventory; POPDI = Pelvic Organ Prolapse Distress Inventory; 
CRADI = Colo-rectal-anal Distress Inventory; PROMIS = Patient-Reported Outcomes Measurement Information System; 
GI=Gastrointestinal 
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